作者: Kazuhiro Inoue , Eiji Kumazawa , Hiroshi Kuga , Hiroshi Susaki , Noriko Masubuchi
关键词:
摘要: The pharmacokinetics of DX-8951f were greatly improved by DE-310 with the extremely longer retention in bloodstream, resulting preferential tumor-targeting, and slow release appropriate to camptothecin analog tumor tissue. On basis pharmacokinetic improvement, exhibited enhanced antitumor effects reduced toxicities a single low dose, compared DX-8951f. These preclinical results suggest that is promising agent for cancer treatment. phase I trials are still ongoing recently, interim clinical data have been reported15, 16.